PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
1-Year Return
33.7%
This Quarter Return
+6.59%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$864M
AUM Growth
+$21.2M
(+2.5%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
2.21%
Top 10 Holdings %
Top 10 Hldgs %
32.42%
Holding
103
New
11
Increased
47
Reduced
28
Closed
15
Top Buys
| 1 |
IQVIA
IQV
|
+$17.3M |
| 2 |
GeneDx Holdings
WGS
|
+$16.2M |
| 3 |
Danaher
DHR
|
+$9.25M |
| 4 |
DexCom
DXCM
|
+$8.34M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$7.63M |
Top Sells
| 1 |
Becton Dickinson
BDX
|
+$27.6M |
| 2 |
UnitedHealth
UNH
|
+$26.3M |
| 3 |
Stryker
SYK
|
+$10.8M |
| 4 |
Gilead Sciences
GILD
|
+$9.68M |
| 5 |
Tenet Healthcare
THC
|
+$7.84M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
United Therapeutics
UTHR
$18.3B
| $2.53M | 0.29% |
8,811
-1,421
| -14% | -$408K |
|
77
UroGen Pharma
URGN
$869M
| $2.42M | 0.28% |
176,702
-216,451
| -55% | -$2.97M |
|
78
Apogee Therapeutics
APGE
$2.2B
| $2.41M | 0.28% |
55,404
+8,741
| +19% | +$380K |
|
79
Precigen
PGEN
$1.13B
| $2.19M | 0.25% |
1,542,823
-1,648,520
| -52% | -$2.34M |
|
80
Crinetics Pharmaceuticals
CRNX
$3.2B
| $2.11M | 0.24% |
73,412
+9,472
| +15% | +$272K |
|
81
Pulmonx
LUNG
$69.3M
| $1.57M | 0.18% |
605,029
-6,846
| -1% | -$17.7K |
|
82
Ardelyx
ARDX
$1.59B
| $1.18M | 0.14% |
301,086
+91,505
| +44% | +$359K |
|
83
Annexon
ANNX
$266M
| $970K | 0.11% |
404,194
+52,758
| +15% | +$127K |
|
|
ATYR
84
aTyr Pharma
ATYR
$591M
| $761K | 0.09% |
+150,000
| New | +$761K |
|
85
908 Devices
MASS
$202M
| $713K | 0.08% |
+100,000
| New | +$713K |
|
86
Entera Bio
ENTX
$82.2M
| $676K | 0.08% |
355,822
-83,810
| -19% | -$159K |
|
|
EDAP
87
EDAP TMS
EDAP
$91.6M
| $255K | 0.03% |
154,832
| – | – |
|
88
ResMed
RMD
$39.6B
| – | – |
-22,622
| Closed | -$5.06M |
|
|
SLN
89
Silence Therapeutics
SLN
$213M
| – | – |
-401,746
| Closed | -$1.13M |
|
|
90
UnitedHealth
UNH
$319B
| – | – |
-50,213
| Closed | -$26.3M |
|
91
VYNE Therapeutics
VYNE
$7.91M
| – | – |
-217,978
| Closed | -$344K |
|
92
Alkermes
ALKS
$4.45B
| – | – |
0
| – | – |
|
|
93
Becton Dickinson
BDX
$53.6B
| – | – |
-120,283
| Closed | -$27.6M |
|
94
Guardant Health
GH
$6.85B
| – | – |
-89,329
| Closed | -$3.81M |
|
|
ICAD
95
DELISTED
iCAD Inc
ICAD
| – | – |
-781,670
| Closed | -$1.61M |
|
96
Insmed
INSM
$30.8B
| – | – |
-37,901
| Closed | -$2.89M |
|
97
Ironwood Pharmaceuticals
IRWD
$213M
| – | – |
-205,086
| Closed | -$301K |
|
98
Keros Therapeutics
KROS
$636M
| – | – |
-217,753
| Closed | -$2.22M |
|
99
Maravai LifeSciences
MRVI
$386M
| – | – |
-660,000
| Closed | -$1.46M |
|
100
NewAmsterdam Pharma
NAMS
$2.72B
| – | – |
-100,955
| Closed | -$2.07M |
|